GBM-Enabled CGM Sensor

About Carbometrics

Carbometrics is a private, pre-revenue biotech spin-out from the University of Bristol, leveraging foundational intellectual property from the acquisition of Ziylo by Novo Nordisk. Its core asset is a proprietary synthetic Glucose Binding Molecule (GBM), published in Nature Chemistry, which offers exceptional selectivity, stability, and signal-coupling versatility for glucose sensing. The company is focused on partnering its GBM platform to enhance the performance of CGM devices, targeting improved accuracy, longevity, and reduced interference in the rapidly expanding digital health and diabetes management markets.

Therapeutic Areas

Other Diabetes Glucose Monitoring Drugs